Form 4: 4D Molecular Therapeutics Chief Legal Officer Scott Bizily Executes Stock Option and Sells Shares
SEC Form 4 Filing
Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- On March 27, 2024, Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options to acquire 4,342 and 1,491 shares of common stock at a price of $25.98 per share.
- Following the exercise of these options, Bizily sold 5,833 shares of common stock at a weighted average price of $35.0438, with individual transactions ranging from $35.00 to $35.20.
- After these transactions, Bizily directly owns 1,737 shares of common stock.
- Bizily also holds options to purchase 55,658 and 54,167 shares of common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard disclosure of insider trading activity under a pre-existing plan.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to have pre-arranged trading plans to avoid accusations of trading on inside information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-arranged nature of the trades mitigates concerns about insider information being used.
Key Dates
| Date | Description |
|---|---|
| October 10, 2023 | Date the Reporting Person adopted the 10b5-1 trading plan. |
| March 27, 2024 | Date of the stock option exercise and stock sale transactions. |
| March 29, 2024 | Date of signature on the Form 4 filing. |
| September 30, 2031 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.